NCT03190824 - Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 22, 2016

Primary Completion Date

June 24, 2021

Study Completion Date

October 31, 2021

Conditions

Melanoma Stage IIIMelanoma Stage Iv

Interventions

DRUG

OBP-301

A novel, replication-competent Ad5 based adenoviral construct that incorporates a human telomerase reverse transcriptase gene (hTERT) promoter.

Trial Locations (1)

Research Site, Morristown